DS
MLTX icon

David Shaw’s MoonLake Immunotherapeutics MLTX Stock Holding History

David Shaw’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-92,300
Closed -$662K – 4858
2025
Q3 		$662K Buy
+92,300
New +$4.81M ﹤0.01% 3710

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
California State Teachers Retirement System (CalSTRS)
California State Teachers Retirement System (CalSTRS) West Sacramento, California $782B AUM 28.39% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

David Shaw's MLTX Position: Q2 2026 in Review

David Shaw increased its MoonLake Immunotherapeutics (MLTX) stake by 41% in Q2 2026, buying an estimated $17.7M and bringing the position to 3,365,507 shares worth $65.5M. The position accounts for 0.03% of the portfolio, ranked #626.

David Shaw first reported a position in MLTX in Q2 2021 and has held it in 8 quarters since. 172 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

  • David Shaw held 3,365,507 shares of MoonLake Immunotherapeutics worth $65.5M as of Q2 2026.
  • David Shaw bought 974,846 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $17.7M.
  • MoonLake Immunotherapeutics made up 0.03% of David Shaw's portfolio in Q2 2026, its #626 holding.
  • David Shaw first reported a position in MoonLake Immunotherapeutics in Q2 2021 and has held it in 8 quarters since.
  • 172 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.